Increasing Tysabri dosing interval may cut PML risk

[MSUK]

Freedom from relapse was maintained in multiple sclerosis patients on Tysabri who received the infusion drug less frequently than the recommended 4-week interval, with lower risk of progressive multifocal leukoencephalopathy (PML), preliminary results from an ongoing analysis have indicated...... Read More - http://www.ms-uk.org/tysabri

[NHE]

Prior to any flag waving, please note that this is not a randomized double blind controlled trial...

Weinshenker commented that selection of patients for extended dosing, which was not random, might have involved "biases against committing more aggressive MS patients on the extended interval program, which might reduce the ability of the investigators to detect reduction in efficacy."